ABSTRACT
OBJECTIVE: To evaluate the role of budesonide inhalation suspension (BIS) in the treatment of children with asthma. DATA SOURCES: Literature identified through Medline (1966-November 2000) and references obtained from selected articles. Search terms included budesonide and asthma. DATA SYNTHESIS: Asthma is a chronic inflammatory disease that affects approximately 4.8 million children in the US. By reducing inflammation, corticosteroids decrease symptoms and improve lung function. As the first nebulized corticosteroid, BIS offers an important treatment option for children with persistent asthma. CONCLUSIONS: BIS is effective in reducing symptoms and improving lung function in children with asthma. It should be used in children ages 1-8 years with moderate to severe persistent asthma who are unable to effectively use a metered-dose inhaler with or without a spacer or a dry-powder inhaler.
Subject(s)
Asthma/drug therapy , Bronchodilator Agents/therapeutic use , Budesonide/therapeutic use , Administration, Inhalation , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/adverse effects , Budesonide/administration & dosage , Budesonide/adverse effects , Child , Humans , MEDLINE , Randomized Controlled Trials as Topic , Suspensions , Treatment OutcomeABSTRACT
Present evidence suggests that the most important nutritional factor bearing on the risk of development of diabetes mellitus is an excessive caloric intake. Other evidence suggests that both dietary prevention of diabetes and mitigation of hyperglycemia by dietary means can prevent morbidity and mortality from the microvascular lesions of diabetes. Diet also has potential for reducing the extent of atherosclerotic lesions associated with the disease.
